LRIG1 Protein

Leucine-rich repeats and immunoglobulin-like domains 1

LRIG1 Products

LRIG1 Protein, Recombinant

Molecule	Species	Description	Cat. No
LRIG1	Mouse	LRIG1 Protein, Recombinant	50511-M08H

LRIG1 cDNA Clone

Molecule	Species	Description	Cat. No
LRIG1	Mouse	Mouse LRIG1 cDNA Clone / ORF Clone	MG50511-M

LRIG1 Related Areas

Cancer>>Growth Factor & Receptor>>EGF Family & Receptor>>LRIG1

LRIG1 Alternative Names

LRIG1, DKFZp586O1624, LIG-1, LIG1 [Homo sapiens]

Lrig1, D6Bwg0781e, Img, LIG-1 [Mus musculus]

LRIG1 Background

Leucine-rich repeats and immunoglobulin-like domains protein 1(termed LRIG1) is a transmembrane protein containing leucine-rich repeats and Ig-like domains in its extracellular region. LRIG1 acts in a negative feedback loop to regulate the activity of Ret receptor tyrosine kinase and has been shown to interact with receptor tyrosine kinases of the EGFR-family, MET and RET. Co-expression of LRIG1 with EGF receptor suppresses cellular receptor levels, shortens receptor half-life, and enhances ligand-stimulated receptor ubiquitination. Co-expression of LRIG1 suppresses EGF-stimulated transformation of NIH3T3 fibroblasts and that the inducible expression of LRIG1 in PC3 prostate tumor cells suppresses EGF- and neuregulin-1-stimulated cell cycle progression. Thus, LRIG1 is a negative regulator of the ErbB family of receptor tyrosine kinases and LRIG1-mediated receptor ubiquitination and degradation may contribute to the suppression of ErbB receptor function. LRIG1 act as a feedback negative regulator of signaling by receptor tyrosine kinases, through a mechanism that involves enhancement of receptor ubiquitination and accelerated intracellular degradation. In neuronal cells, LRIG1 overexpression also inhibits GDNF/Ret-induced neurite outgrowth in a cell-autonomous manner. Downregulation of LRIG1 potentiates both neuronal differentiation and MAPK activation in response to GDNF.

LRIG1 Related Studies

1. Shattuck DL, et al. (2007) LRIG1 Is a Novel Negative Regulator of the Met Receptor and Opposes Met and Her2 Synergy. Mol Cell Biol. 27 (5): 1934-46.
2. Ledda F, et al. (2008) Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci. 28(1): 39-49.
3. Hedman H, et al. (2002) Is LRIG1 a tumour suppressor gene at chromosome 3p14.3 Acta Oncol. 41(4): 352-4.